GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Ligand Pharmaceuticals Incorporated (LGND) [hlAlert]

Rating:
Mkt Outperform
LGND
up 740.01 %

Ligand Pharmaceuticals Incorporated (LGND) rated Mkt Outperform with price target $5 by Rodman & Renshaw

Posted on: Wednesday,  Nov 26, 2008  8:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) on 11/26/2008, when the stock price was $11.22.
Since then, Ligand Pharmaceuticals Incorporated has gained 740.02% as of 09/30/2015's recent price of $94.25.
If you would have followed this Rodman & Renshaw's recommendation on LGND, you would have gained 740.01% of your investment in 2499 days.

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/26/2008 8:25 AM Buy
None
11.22 30.00
as of 12/24/2008
1 Week down  -1.40 %
1 Month up  2.18 %
3 Months   
1 YTD up  2.18 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy